The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Now a number of people have contacted me about a recent study suggesting that Alpha-GPC when taken chronically over many years could increase one's vulnerability to stroke. I've looked at those data and my read of the data is that they're not very conclusive
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
how, by what mechanism that is, could Alpha-GPC be increasing the susceptibility to stroke? And it seems to be related to increases in TMAO, which is a marker related to the cardiovascular system.